{"id":54357,"date":"2023-03-01T03:03:32","date_gmt":"2023-03-01T02:03:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/"},"modified":"2023-03-01T03:03:32","modified_gmt":"2023-03-01T02:03:32","slug":"2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/","title":{"rendered":"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–2seventy bio, Inc. (\u201c2seventy bio\u201d) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at a public offering price of $11.50 per share. All of the shares in the offering are being offered by 2seventy bio. In addition, 2seventy bio has granted the underwriters a 30-day option to purchase up to an additional 1,630,434 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about March 3, 2023, subject to the satisfaction of customary closing conditions.\n<\/p>\n

<\/a><\/p>\n

\nGoldman Sachs & Co. LLC, Cowen and Company, LLC and SVB Securites LLC are acting as joint book-running managers for the offering.\n<\/p>\n

\nThe shares of common stock are being offered by 2seventy bio pursuant to 2seventy bio\u2019s registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2022 and became effective on November 18, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on February 28, 2023. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (866) 471-2526, facsimile: (212) 902-9316, email: prospectus-ny@ny.email.gs.com<\/a>; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at Prospectus_ECM@cowen.com<\/a> or by telephone at (833) 297-2926; or SVB Securities LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at syndicate@svbsecurities.com<\/a>; or by accessing the SEC\u2019s website at www.sec.gov<\/a>.\n<\/p>\n

\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\n<\/p>\n

\nAbout 2seventy bio<\/b>\n<\/p>\n

\nOur name, 2seventy bio, reflects why we do what we do – TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action \u2013 270 miles per hour \u2013 to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape.\n<\/p>\n

\nWith a deep understanding of the human body\u2019s immune response to tumor cells and how to translate cell therapies into practice, we\u2019re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to \u201cthink\u201d smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our \u201cwhy\u201d and keeping our people and culture top of mind every day.\n<\/p>\n

\n2seventy bio is a trademark of 2seventy bio, Inc.\n<\/p>\n

\nCautionary Note Regarding Forward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the closing of 2seventy bio\u2019s anticipated public offering. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.\n<\/p>\n

\nAny forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and statements regarding the timing, size and expected gross proceeds of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities, and 2seventy bio\u2019s ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled \u201cRisk Factors\u201d in 2seventy bio\u2019s most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in 2seventy bio\u2019s other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering to be filed with the SEC. Any forward-looking statements contained in this press release represent 2seventy bio\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. 2seventy bio explicitly disclaims any obligation to update any forward-looking statements, except as required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Elizabeth Pingpank
\n
860-463-0469
\n
elizabeth.pingpank@2seventybio.com<\/a>\n<\/p>\n

\nMedia:<\/b>
Jenn Snyder
\n
617-448-0281
\n
jenn.snyder@2seventybio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–2seventy bio, Inc. (\u201c2seventy bio\u201d) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at a public offering price of $11.50 per share. All … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54357","6":"format-standard","7":"category-industry"},"yoast_head":"\n2seventy bio Announces Pricing of Upsized Public Offering of Common Stock - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–2seventy bio, Inc. (\u201c2seventy bio\u201d) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at a public offering price of $11.50 per share. All ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-01T02:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230228006498\/en\/1257457\/21\/2seventy_logo_for_BW.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock\",\"datePublished\":\"2023-03-01T02:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/\"},\"wordCount\":923,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228006498\\\/en\\\/1257457\\\/21\\\/2seventy_logo_for_BW.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/\",\"name\":\"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228006498\\\/en\\\/1257457\\\/21\\\/2seventy_logo_for_BW.jpg\",\"datePublished\":\"2023-03-01T02:03:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228006498\\\/en\\\/1257457\\\/21\\\/2seventy_logo_for_BW.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228006498\\\/en\\\/1257457\\\/21\\\/2seventy_logo_for_BW.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/","og_locale":"en_US","og_type":"article","og_title":"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–2seventy bio, Inc. (\u201c2seventy bio\u201d) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at a public offering price of $11.50 per share. All ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-01T02:03:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230228006498\/en\/1257457\/21\/2seventy_logo_for_BW.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock","datePublished":"2023-03-01T02:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/"},"wordCount":923,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230228006498\/en\/1257457\/21\/2seventy_logo_for_BW.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/","url":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/","name":"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230228006498\/en\/1257457\/21\/2seventy_logo_for_BW.jpg","datePublished":"2023-03-01T02:03:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230228006498\/en\/1257457\/21\/2seventy_logo_for_BW.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230228006498\/en\/1257457\/21\/2seventy_logo_for_BW.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/2seventy-bio-announces-pricing-of-upsized-public-offering-of-common-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"2seventy bio Announces Pricing of Upsized Public Offering of Common Stock"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54357"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54357\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}